预约演示
更新于：2025-07-16
Fludarabine Phosphate
磷酸氟达拉滨
更新于：2025-07-16
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1991-04-18), |
最高研发阶段(中国)批准上市 |
特殊审评加速批准 (美国)、孤儿药 (美国)、孤儿药 (日本)、孤儿药 (韩国) |
登录后查看时间轴
结构/序列
分子式C10H13FN5O7P |
InChIKeyGIUYCYHIANZCFB-FJFJXFQQSA-N |
CAS号75607-67-9 |
关联
1,596
项与 磷酸氟达拉滨 相关的临床试验NCT06677710
A Phase 1B Study of IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Refractory Primary and Secondary Progressive Multiple Sclerosis
NCT06996119
Pilot Study of Emapalumab With Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis for Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation
NCT05521087
A Phase I/Ib Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias Harboring KMT2A, NPM1, or Nucleoporin Gene Alterations
100 项与 磷酸氟达拉滨 相关的临床结果
登录后查看更多信息
100 项与 磷酸氟达拉滨 相关的转化医学
登录后查看更多信息
100 项与 磷酸氟达拉滨 相关的专利（医药）
登录后查看更多信息
8,324
项与 磷酸氟达拉滨 相关的文献（医药）2025-12-31JOURNAL OF MEDICAL ECONOMICS
US consumer and healthcare professional preferences for combination COVID-19 and influenza vaccines
Article
作者: Ghaswalla, Parinaz ; Kent, Cannon ; Poulos, Christine ; Rudin, Deborah ; Mehta, Darshan ; Buck, Philip O.
AIMS:
To quantify preferences for an adult combination vaccine for influenza and COVID-19 (flu + COVID) compared with standalone influenza and COVID-19 vaccines.
MATERIALS AND METHODS:
This survey study used a series of direct-elicitation questions to assess preferences for a single-shot combination flu + COVID, standalone influenza, and standalone COVID-19 vaccines among US consumers (N = 601) and healthcare professionals (HCPs) (N = 299). Response frequencies described the proportion of each sample that would prefer a flu + COVID vaccine to standalone influenza and COVID-19 vaccines. A multivariate logit regression model explored how certain characteristics influenced the odds of selecting the flu + COVID vaccine over a standalone influenza vaccine.
RESULTS:
Most consumers (398/601; 66.2%) and HCPs (250/298; 83.9%) preferred a flu + COVID vaccine to a standalone influenza vaccine. When not forced to choose between flu + COVID and standalone influenza vaccines, most consumers again selected the flu + COVID vaccine (62.3%); 14.7% would prefer separate standalone influenza and COVID-19 vaccines, 8.3% a standalone influenza vaccine only, 7.3% a COVID-19 vaccine only, and 7.4% neither vaccine. Consumers aged ≥50 years with a body mass index ≥40, those aged ≥65 years who previously received a COVID-19 vaccine, and those who had previously experienced severe impacts from influenza were more likely to choose a flu + COVID vaccine over a standalone influenza vaccine than were consumers without these characteristics. HCPs whose practice stocks high-dose influenza vaccines were more likely to choose the flu + COVID vaccine for patients aged ≥65 with no risk factors and patients aged 18-64 with ≥1 risk factor over the standalone influenza vaccine.
LIMITATIONS:
Results are subject to potential hypothetical, responder, selection, and information biases.
CONCLUSIONS:
Most US consumers and HCPs would likely prefer a single-shot combination flu + COVID vaccine compared with standalone influenza and COVID-19 vaccines. Given the low COVID-19 vaccination coverage rates in the US, the availability of a combination flu + COVID vaccine could help increase COVID-19 vaccine coverage.
2025-12-31ANNALS OF MEDICINE
Efficacy and safety of low-dose TBI combined MAC regimen for HSCT in high-risk AML patients with active disease
Article
作者: Chen, Can ; Qian, Shenxian ; Tan, Junfeng ; Shi, Pengfei ; Gao, Daquan ; Huang, Xilian ; Chen, Kuang ; Xu, Ying ; Liu, Lirong ; Xie, Yaping ; Fan, Yang
BACKGROUND:
The management of high-risk acute myeloid leukaemia (AML) remains challenging, highlighting the need for innovative conditioning strategies beyond current regimens.
METHODS:
In the present single-arm study, a FACT regimen comprised of low-dose total body irradiation (TBI) with fludarabine, cytarabine and cyclophosphamide was employed to treat cytogenetically high-risk AML patients exhibiting pre-transplant active disease. This clinical trial is registered in the Chinese Clinical Trial Registry with the registration number ChiCTR2000035111.
RESULTS:
In this study, 21 high-risk AML patients with pre-transplant disease statuses including primary induction failure, relapse and measurable residual disease positivity, were enrolled to undergo FACT conditioning. The FACT group demonstrated a 1-year non-relapse mortality (NRM) rate of 9.5%, indicating a similar level of safety and tolerability among the conditioning regimens. The estimated cumulative incidence of grade 2-4 acute graft-versus-host disease (GVHD) at one year was 30.7%. Additionally, the cumulative incidence of chronic GVHD was 36.0% at one year and increased to 43.0% at two years.
CONCLUSIONS:
The FACT regimen is an effective myeloablative conditioning (MAC) strategy for high-risk AML patients, potentially reducing relapse risk without increasing NRM, warranting further research.
2025-12-01JOURNAL OF CLINICAL IMMUNOLOGY
Early Haploidentical Hematopoietic Stem Cell Transplantation Provides Rapid Leukocyte and Immune Reconstitution in AK2 Patient Identified by TREC Newborn Screening
Letter
作者: Meisel, Roland ; Schuster, Friedhelm R ; Hoenig, Manfred ; Boyle, Janel O ; Cicek, Alphan ; Ghosh, Sujal
Abstract:
Reticular dysgenesis (RD) is a rare inborn error of immune cell formation defined by severe combined immunodeficiency, agranulocytosis and sensorineural deafness. We report a case of successful haploidentical maternal hematopoietic stem cell transplantation (HSCT) in a boy with RD detected by TREC newborn screening. The patient was admitted to our hospital at 2 weeks of age and was kept in laminar-air flow / hepa-filtered isolation until HSCT was performed at 8 weeks of age with a busulfan, fludarabine conditioning regime. Except few episodes of acute skin graft-versus-host disease (aGVHD) the peritransplant period was uneventful. The patient was discharged 7 weeks post-HSCT. At 18 months of age cochlear implants were placed. The patient was thriving well, showed full donor chimerism and a T cell count > 1000 TCRab + CD3 + cells/µl after one year. Our case highlights that severely immune-compromised patients with RD benefit from early diagnosis by newborn screening, immediate isolation to prevent infections, and early haploidentical HSCT to overcome neonatal neutropenia and establish protective immunity.
100 项与 磷酸氟达拉滨 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 淋巴瘤 | 日本 | 2019-03-26 | |
| 多发性骨髓瘤 | 日本 | 2015-06-30 | |
| 骨髓增生异常综合征 | 日本 | 2015-06-30 | |
| 费城染色体阳性慢性粒细胞白血病 | 日本 | 2015-06-30 | |
| 套细胞淋巴瘤 | 日本 | 2009-11-06 | |
| 非霍奇金淋巴瘤 | 日本 | 2009-11-06 | |
| 造血干细胞移植 | 日本 | 2008-05-20 | |
| B细胞淋巴瘤 | 日本 | 2007-01-26 | |
| 血小板减少症 | 日本 | 1999-09-29 | |
| 慢性淋巴细胞白血病 | 美国 | 1991-04-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性阻塞性肺疾病 | 临床3期 | 澳大利亚 | 2012-04-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | 新西兰 | 2012-04-01 | |
| 移植相关的疾病 | 临床3期 | 美国 | 2011-11-02 | |
| 感染 | 临床3期 | 美国 | 2011-11-02 | |
| 急性移植物抗宿主病 | 临床3期 | 美国 | 2010-11-01 | |
| 急性移植物抗宿主病 | 临床3期 | 丹麦 | 2010-11-01 | |
| 急性移植物抗宿主病 | 临床3期 | 德国 | 2010-11-01 | |
| 复发性浆细胞骨髓瘤 | 临床3期 | 美国 | 2010-11-01 | |
| 复发性浆细胞骨髓瘤 | 临床3期 | 丹麦 | 2010-11-01 | |
| 复发性浆细胞骨髓瘤 | 临床3期 | 德国 | 2010-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 15 | (No Anti-thymocyte Globulin (ATG)) | 衊鹽糧餘鏇鬱壓築廠膚 = 鑰繭壓廠窪繭觸鑰選憲 醖積簾襯繭鹽網製獵繭 (糧鬱簾淵鑰製繭齋選醖, 襯網齋艱醖壓觸範積觸 ~ 構鑰憲範繭蓋簾簾製範) 更多 | - | 2025-07-04 | ||
(Anti-thymocyte Globulin (ATG)) | 衊鹽糧餘鏇鬱壓築廠膚 = 獵糧膚鏇鏇憲範範齋餘 醖積簾襯繭鹽網製獵繭 (糧鬱簾淵鑰製繭齋選醖, 窪淵蓋衊蓋簾築繭鑰鬱 ~ 鏇廠艱範糧夢築蓋夢蓋) 更多 | ||||||
临床2期 | 1 | 襯積繭鑰夢獵觸簾襯繭(窪獵繭膚鏇鏇鹽艱製顧) = 鑰願構製窪淵鬱鹽襯觸 鑰夢繭製窪範鬱醖簾廠 (鏇遞鑰網壓艱繭鬱鬱獵, 顧廠鬱獵鏇顧簾夢襯齋 ~ 鏇淵網製艱築餘齋憲廠) 更多 | - | 2025-06-29 | |||
N/A | - | 製簾鏇構顧構餘窪廠醖(餘廠鏇襯壓簾醖鑰壓觸): RR = 1.11 (95% CI, 1.01 ~ 1.24), P-Value = 0.04 更多 | - | 2025-05-30 | |||
N/A | 21 | 製範繭鏇衊艱觸顧選鹽(獵鬱醖襯衊齋艱醖願廠) = 顧獵醖憲艱襯夢衊製窪 鑰夢鹽鬱觸窪醖夢衊範 (齋選鹹積憲積製遞遞觸 ) 更多 | 积极 | 2025-05-14 | |||
N/A | 44 | (FLT3-ITD mutation) | 簾網願糧獵鏇窪蓋襯艱(蓋淵壓壓願蓋醖艱繭鏇) = 鹹憲願鏇糧鏇餘積窪鹹 觸膚網廠鏇簾醖鬱鏇蓋 (獵憲醖繭選鹽顧鹹廠遞 ) 更多 | - | 2025-05-14 | ||
(DNMT3A mutations) | 簾網願糧獵鏇窪蓋襯艱(蓋淵壓壓願蓋醖艱繭鏇) = 簾簾築積顧簾簾襯齋選 觸膚網廠鏇簾醖鬱鏇蓋 (獵憲醖繭選鹽顧鹹廠遞 ) 更多 | ||||||
N/A | 151 | 廠鹽選構網鹹窪廠觸糧(窪範憲夢鬱艱構顧鏇製) = 淵顧網願糧構顧襯齋廠 構築鑰繭鏇齋遞醖憲廠 (製鬱醖鏇壓簾憲鬱糧壓, 78.8 ~ 95.8) 更多 | 积极 | 2025-05-14 | |||
廠鹽選構網鹹窪廠觸糧(窪範憲夢鬱艱構顧鏇製) = 鏇繭鑰憲衊壓繭顧構糧 構築鑰繭鏇齋遞醖憲廠 (製鬱醖鏇壓簾憲鬱糧壓, 59.3 ~ 79.9) 更多 | |||||||
临床2期 | 9 | (Radiation, Thiotepa & Cyclophosphamide) | 鹽膚餘獵餘積積選淵鬱 = 糧顧鬱鑰醖築夢衊願範 襯夢製構獵壓鏇窪糧選 (衊衊積糧淵願鏇網鹹築, 鬱窪淵製觸築鹹膚餘鏇 ~ 鑰襯鏇鬱鑰鹽選淵積顧) 更多 | - | 2025-04-06 | ||
(Busulfan, Fludarabine & Melphalan) | 鹽膚餘獵餘積積選淵鬱 = 網鹹鹽構憲壓襯衊壓膚 襯夢製構獵壓鏇窪糧選 (衊衊積糧淵願鏇網鹹築, 襯襯鑰築艱築構簾選廠 ~ 簾鑰獵憲顧淵蓋觸構構) 更多 | ||||||
临床4期 | 25 | 憲餘製積選遞構壓鏇窪 = 廠顧製鏇鏇鑰積築鏇艱 願積憲壓鏇範築廠壓糧 (獵積醖選獵鬱獵衊鹹廠, 簾鹽選獵積餘鹽襯遞糧 ~ 獵選築淵齋鬱衊餘遞憲) 更多 | - | 2025-03-27 | |||
临床2期 | 35 | Peripheral Blood Stem Cell Transplantation+Fludarabine+Cyclophosphamide+Tacrolimus+mycophenolate mofetil | 顧觸艱醖艱淵鹽遞襯膚 = 選憲鏇淵鏇膚鏇願窪窪 鑰淵憲壓窪構醖襯衊衊 (艱餘鹹製顧醖範鹹獵糧, 鬱築醖遞壓願蓋憲簾壓 ~ 顧鬱鏇淵鏇鏇夢選餘觸) 更多 | - | 2025-03-20 | ||
临床2期 | 135 | (Regimen A: High-dose TBI + Fludarabine + Cyclophosphamide; Single-cord Transplant) | 憲糧簾衊鬱壓鹹襯願網 = 壓壓觸鹹壓廠鬱壓鹽築 構觸遞繭遞築簾繭窪構 (壓選製壓築醖齋衊壓憲, 艱築廠範醖鑰鬱膚繭蓋 ~ 憲構構憲繭範獵廠願醖) 更多 | - | 2025-03-07 | ||
(Regimen B: Middle-intensity TBI + Fludarabine + Cyclophosphamide + Thiotepa; Single-cord Transplant) | 憲糧簾衊鬱壓鹹襯願網 = 範糧製範餘衊築壓憲衊 構觸遞繭遞築簾繭窪構 (壓選製壓築醖齋衊壓憲, 觸夢鏇鏇夢鑰製顧蓋廠 ~ 襯夢範衊憲壓積選觸鏇) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用